Abstract |
An intravenous (i.v.) formulation of itraconazole was evaluated in disseminated fungal infection models in guinea pigs. In acute disseminated Candida albicans and Aspergillus fumigatus infections, treatment at 5 mg/kg of body weight twice a day (b.i.d.) significantly prolonged survival. In these models and in animals with chronic disseminated cryptococcosis, itraconazole given i.v. at 2.5 and 5 mg/kg b.i.d. greatly reduced the proportions of organs with culture-detectable fungal burdens. The efficacy of i.v. itraconazole in these animal models justifies its further investigation for the treatment of life-threatening mycoses in humans.
|
Authors | F C Odds, M Oris, P Van Dorsselaer, F Van Gerven |
Journal | Antimicrobial agents and chemotherapy
(Antimicrob Agents Chemother)
Vol. 44
Issue 11
Pg. 3180-3
(Nov 2000)
ISSN: 0066-4804 [Print] United States |
PMID | 11036047
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antifungal Agents
- Itraconazole
|
Topics |
- Animals
- Antifungal Agents
(blood, therapeutic use)
- Aspergillosis
(drug therapy)
- Aspergillus fumigatus
(drug effects)
- Candida albicans
(drug effects)
- Candidiasis
(drug therapy)
- Cryptococcosis
(drug therapy)
- Cryptococcus neoformans
(drug effects)
- Disease Models, Animal
- Guinea Pigs
- Itraconazole
(blood, therapeutic use)
- Treatment Outcome
|